Element Materials Technology, a global provider of testing, inspection and certification services, announced it has completed the acquisition of JMI Laboratories in North Liberty. The deal marks the sixth life sciences-focused acquisition for London-based Element, which has expanded its team to more than 1,000 experts in 23 facilities across North America and Europe. JMI conducts antimicrobial-resistance monitoring studies used for U.S. Food and Drug Administration regulatory and new drug application submissions, through its Sentry Antimicrobial Surveillance Program. It offers microbiology and molecular testing services to assist in the development of new antimicrobials and clinical trial support. “Our expansion into life sciences and connected technologies over the last two years has seen us gain a leadership position in these strategically important end-markets,” Element CEO Jo Wetz said in a press release. “As we celebrate 10 years of being a standalone Element business, we see more and more opportunities to work closely with our customers throughout their product and testing lifecycles.”